A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines

Creative Commons License

Temel M., Atagunduz P., Direskeneli H.

ANNALS OF THE RHEUMATIC DISEASES, cilt.64, sa.9, ss.1383-1384, 2005 (SCI-Expanded, Scopus) identifier identifier identifier